Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Professor John Andrew Todd © Novo Nordisk / © Stephen Foote

Professor John Andrew Todd – Professor of Precision Medicine and Director of the Wellcome Centre for Human Genetics and of the JDRF/Wellcome Diabetes and Inflammation Laboratory (DIL) – was honoured for his world-class research that potentially foresees type 1 diabetes and daily insulin injections as a thing of the past.

He said: ‘My first thought was that I was overwhelmed and very honoured to receive the prize. And my second was for type 1 diabetes, because the disease is the overlooked little brother of type 2. Well, this is changing.

‘I think the scientific community underestimates what a burden it is to have a child with type 1 diabetes even if that child is using all the modern devices. Night-time is still a worry, for example, because a child might have a hypoglycaemic episode. So, I thank all the people with whom I have worked on type 1 diabetes and brought the field to where it is today.’

Read the full story on the University of Oxford website.